Clinical manifestations associated to anti-Ro/SS-A antibodies in Systemic Lupus Erythematosus and Sjögren's Syndrome diagnosed patients

M CALVO; M LÓPEZ MEILLER; A. PELUZZONI; MARÍA PINO; MARIELA L. PAZ; DANIEL H. GONZÁLEZ MAGLIO; MALIANDI M; JULIANA LEONI; GUSTAVO NASSWETTER

Perú

Congreso; XIV Congress of the Pan-american league of associations for rheumatology (PANLAR); 2006

Abstract: The presence of anti-Ro/SSA antibody and its subtypes, Ro 52 kDa and Ro 60 kDa, has been associated with the clinical features in patients with systemic lupus erythematosus (SLE) and Sjogren´s syndrome (SS), although there are many contradictory reports about it.Objective: To establish the association between total anti-Ro/SSA, Ro/SSA 52 kDa and Ro/SSA 60 kDa, and clinical features in patients with LES und SS.Methods: Anti-Ro/SSA antibodies were determined in sera from 59 patients with diagnosed SLE (according to the ACR classification criteria, 1999), and 34 patients with diagnosed primary SS (pSS) and SS secondary (sSS) to other collagenopathies that are not SLE (according to the American-European Consensus Group classification criteria, 2002), by 2 ELISA methods. A commercial ELISA (#1), where total anti-Ro/SSA antibodies are detected, and ELISA (#2), which uses recombinant proteins to detect anti-Ro/SSA 52 and 60 kDa. The following clinical features were analyzed in the 93 patients: xerostomia, xerophthalmia, arthralgia, arthritis, photosensitivity, malar rash, central nervous system compromise and hematological compromlse.Results: Front 166 evaluated patients, 93 met the inclusion criteria, these were diagnosed: 59 as SLE and 34 as pSS or sSS. From the 59 SLE patients, 30 were anti-Ro/SSA negative and 29 positive, among the last group 18 were double positive (Ro 52 and 60 kDa), 6 showed only anti-Ro 52 antibodies, and 5 were only positive by ELISA #l. Anti-Ro 60 kDa were not found isolated. Statistically significant differences between the anti-Ro subtypes and the studied clinical features were not found. Thirteen patients with diagnosed SS were anti-Ro/SSA negative, 14 were double positive and 7 showed only anti-Ro 52 antibodies. Anti-Ro 60 kDa were not found isolated either. The total (100%) of the SS patients with anti-Ro 52 antibodies presented xerostomia and xerophtalmia. Statistically significant differences among the other studied clinical features were not found.Conclusions: Differences in the clinical manifestations studied could not be correlated with the presence of any of the 2 types of anti-Ro/SSA antibodies.